Liraglutide’s FDA Panel For Weight Loss Is Test Of Diabetes Experience
This article was originally published in The Pink Sheet Daily
Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.
You may also be interested in...
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
Aetna has issued a revised clinical policy bulletin that includes Qsymia and Belviq among the drugs it considers to be “medically necessary weight reduction medications” when a series of criteria are met.